Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million and a net loss of $131.01 million. Despite setbacks, advancements in clinical trials and partnerships with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results